The rise of marine fungi: Drug discovery's blue frontier

References

[1] Laxminarayan R. The overlooked pandemic of antimicrobial resistance. Lancet. 2022; 399: 606-607.

[2] Murray CJL, Ikuta KS, Sharara F, et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022; 399: 629-655.

[3] Newman DJ, Cragg GM. Natural products as sources of new drugs over the nearly four decades from 01/1981 to 09/2019. J Nat Prod. 2020; 83: 770-803.

[4] Breyer E, Stix C, Kilker S, et al. The contribution of pelagic fungi to ocean biomass. Cell. 2025; 188: 3992-4002.e3913.

[5] Han B, Feinstein T, Shi Y, et al. Plinabulin plus docetaxel versus docetaxel in patients with non-small-cell lung cancer after disease progression on platinum-based regimen (DUBLIN-3): a phase 3, international, multicentre, single-blind, parallel group, randomised controlled trial. Lancet Respir Med. 2024; 12: 775-786.

[6] Morales SE, Biswas A, Herndl GJ, Baltar F. Global structuring of phylogenetic and functional diversity of pelagic fungi by depth and temperature. Front Mar Sci. 2019; 6: 131.

[7] Lloyd KG, Steen AD, Ladau J, Yin J, Crosby L. Phylogenetically novel uncultured microbial cells dominate earth microbiomes. mSystems. 2018; 3(5): e00055-18.

[8] Carroll AR, Copp BR, Grkovic T, Keyzers RA, Prinsep MR. Marine natural products. Nat Prod Rep. 2025; 42: 257-297.

[9] Ziemert N, Alanjary M, Weber T. The evolution of genome mining in microbes—a review. Nat Prod Rep. 2016; 33: 988-1005.

[10] Peng X, Wu J, Shao C, Li Z, Chen M, Wang C. Co-culture: stimulate the metabolic potential and explore the molecular diversity of natural products from microorganisms. Mar Life Sci Technol. 2021; 3: 363-374.

[11] Stokes JM, Yang K, Swanson K, et al. A deep learning approach to antibiotic discovery. Cell. 2020; 180: 688-702.e613.

RIGHTS & PERMISSIONS

2026 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.